🇺🇸 FDA
Patent

US 10053503

Monoclonal antibodies that neutralize anthrax toxins

granted A61KA61K2039/505A61K51/1009

Quick answer

US patent 10053503 (Monoclonal antibodies that neutralize anthrax toxins) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K51/1009, A61P, A61P31/04